Previous 10 | Next 10 |
2024-06-25 09:45:00 ET It's obvious why Pfizer (NYSE: PFE) is eager to produce a medicine like Wegovy, Novo Nordisk 's (NYSE: NVO) smash-hit obesity therapy that's essentially a slightly different version of its type 2 diabetes drug called Ozempic. With such a gargantuan mar...
2024-06-25 06:53:51 ET Summary Boeing offers to buy Spirit Aero for $35 per share mainly in stock. Novo Nordisk to invest $4.1B in N.C. facility for obesity drugs. Oracle warns TikTok ban in U.S. could impact earnings. Listen below or on the go on Apple Podcasts ...
2024-06-25 05:10:40 ET Novo Nordisk ( NVO ) is up 2.1 % in premarket trade after the company's Wegovy weight loss treatment was approved in the world's second-largest economy.... Read the full article on Seeking Alpha For further details see: Novo Nordisk's Wegov...
2024-06-24 14:51:58 ET More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Lilly, Novo Nordisk to d...
2024-06-24 13:05:06 ET Summary Zealand Pharma A/S petrelintide showed promising results in a phase 1b study, with patients achieving up to 8.6% weight loss over 16 weeks at the highest dose. The global obesity market could reach $77 billion in 2030. Survodutide, dapiglutide, a...
2024-06-24 09:21:19 ET More on Altimmune Altimmune: Going All-In On Pemvidutide Altimmune: A Potential Minor Player In The Massive GLP-1 Space Altimmune's Pemvidutide Is Not To Be Dismissed Altimmune Q1 2024 Earnings Preview Altimmune falls after Q4 r...
2024-06-23 14:00:00 ET More on Eli Lilly, Novo Nordisk Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity SA Asks: Who will launch the next big weight-loss drug? SA Asks: Is Eli Lilly or Novo No...
2024-06-22 11:00:00 ET More on Eli Lilly, Novo Nordisk, etc. Eli Lilly: The Party Is Probably Nearing The End Novo Nordisk: Leading The Fight Against Diabetes And Obesity Eli Lilly And Alzheimer's Disease: The Paucity Of Progress ResMed, Philips under pressur...
2024-06-21 10:03:58 ET More on Catalent Catalent shareholders approve acquisition by Novo Holdings Catalent, Novo Nordisk receive FTC request for more information Seeking Alpha’s Quant Rating on Catalent Historical earnings data for Catalent Fi...
2024-06-21 09:44:16 ET More on Hims & Hers Health Hims & Hers: The Undervalued Gem Poised For Growth Hims & Hers: Compounded Semaglutide Boost Unlikely To Last - Moderate Risks Ahead Hims & Hers: Ready For Takeoff Hims & Hers cut to Neutra...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 05:48:00 ET Novo Nordisk (NYSE: NVO) is riding the Ozempic/Wegovy train straight to the bank. Eli Lilly (NYSE: LLY) is doing the same with Mounjaro and Zepbound. Both big drugmakers have multibillion-dollar obesity drug franchises that continue to grow rapidly. Sh...
2024-07-17 13:21:54 ET Shares of Swiss pharmaceuticals company Roche Holding (OTC: RHHBY) soared 7% through 11:55 a.m. ET Wednesday on positive data from phase 1 clinical trials of its new weight loss drug CT-996. But good news for Roche is bad news for the companies that no...
2024-07-14 05:20:00 ET Two pharma juggernauts, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) , are picking up speed in their preparations for an epic battle to control the market for weight loss drugs. The prize for the victor will be a larger market share of what may b...